baber/WOPTO huggingface dataset:
Patent NZ-520094-A (NZ)
Title: Novel biarylcarboxamides
Inventor: PHILLIPS EIFION
IPC: A61P25/34
Filed: 2001-02-15
Abstract: A compound of formula I; the use of the compound in the manufacture of a medicament for the treatment of prophylaxis of psychotic disorders or intellectual impairment disorders, of human diseases or conditions in which activation of the alpha 7 nicotinic receptor is beneficial and of Alzheimer's disease, learning deficit, cognitive deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntingdon's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain or ulcerative colitis; a process for the preparation of the compound; and a pharmaceutical composition comprising the compound.
Patent NZ-521360-A (NZ)
Title: Improved treatment of neovascularization
Inventor: BRAZZELL ROMULUS KIMBRO
IPC: A61K38/08
Filed: 2001-03-22
Abstract: The use of an anti-angiogenic drug selected from inhibitors of protein kinase C, inhibitors of growth hormone and IGF-1 inhibitors of vascular endothelial growth factor, inhibitors of cyclooxygenase II, inhibitors of NF-kappa B, and PLA2 antagonists in conjunction with a photosensitive agent in the preparation of a medicament for photodynamic treatment of unwanted neovasculature due to CNV (choroidal neovascularization) in a subject.
Patent NZ-529985-A (NZ)
Title: Method for characterizing polypeptides
Inventor: THOMPSON ANDREW
IPC: C07K1/12
Filed: 2002-06-07
Abstract: A method for characterising a polypeptide, which method comprises the steps of: (a) optionally reducing cysteine disulphide bridges in the polypeptide to form free thiols, and capping the free thiols; (b) cleaving the polypeptide with a sequence specific cleavage reagent to form peptide fragments; (c) optionally deactivating the cleavage reagent; (d) capping one or more epsilon-amino groups that are present with a lysine reactive agent, wherein the lysine reactive agent comprises a hindered Michael reagent; (e) analysing peptide fragments by mass spectrometry to form a mass fingerprint for the polypeptide; and (f) determining the identity of the polypeptide from the mass fingerprint.
Patent NZ-530899-A (NZ)
Title: A convenience foodstuff package
Inventor: MATTHEWS ROLAND
IPC: B65D5/54
Filed: 2002-07-26
Abstract: A foodstuff package for convenience foodstuff such as hamburgers/sandwiches. The package includes a foodstuff gripping section (10) which has an elongate wall (11b) with projecting upper flap elements (12a and 12b) and corresponding lower flap elements. In use, the flap elements overlap one another and can be joined together to form respective upper and bottom walls, enabling an item of foodstuff to be gripped. Only a part of the peripheral side of the foodstuff is engaged by the elongate wall.
Patent NZ-533701-A (NZ)
Title: Ultrapure oral fludara formulation with a fast releasing active substance
Inventor: HEIL WOLFGANG
IPC: A61P35/00
Filed: 2002-11-25
Abstract: Disclosed herein is a quick-release tablet formulation that comprises 1 to 100 mg of the active ingredient fludara at a purity of >99.19%, together with Lactose monohydrate, Colloidal silicon dioxide, Microcrystalline cellulose (avicel), Crosscaramellose-Na (sodium carboxymethyl cellulose), and magnesium stearate, characterized in that the contaminants in the fludara do not exceed a percentage as follows: 0.02% 2-Fluoro-9-([beta]-D-arabinofurarnosyl)-9H-purine-6-amine, 0.12% 6-Amino-9(5-O-phosphono-[beta]-D-arabinofuranosyl)-9H-purin-2-ol, 0.02% 2-Fluoro-9H-purine-6-amine, 0.02% 6-Amino-9H-purin-2-ol, 0.05% 2-Fluoro-9-(5-O-phosphono-[beta]-D-ribofuranosyl)-9H-purine-6-amine, 0.1% 9-(3,5-O-diphosphono-[beta]-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine, 0.1% 9-(2,5-O-diphosphono-[beta]-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine, 0.02% 2-Fluoro-9-(5-O-phosphono-[beta]-D-arabinofuranosyl)-9H-purine-6-amine, 0.06% 2-Ethoxy-9-(5-O-phosphono-[beta]-D-arabinofuranosyl)-9H-purine-6-amine, 0.02% 2-(6-Amino-9H-purin-2-yl)-9-(5-O-phosphono-[beta]-D-arabinofuranosyl)-9H-purine-6-amine and O,O'-bis[2-(6-amino-2-fluoro-9H-purin-9-yl)-5-deoxy-[alpha]-D-arabinofuranos-5-yl]-phosphate, 0.1% 9-(2-Chloro-2-deoxy-5-phosphono-[beta]-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine, and 0.1% 9-(2,5-Anhydro-[beta]-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine.
Patent NZ-534104-A (NZ)
Title: Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material
Inventor: LERNER ITZHAK E
IPC: A61K9/22
Filed: 2002-11-12
Abstract: A solid pharmaceutical dosage form for oral administration to a patient comprising a recessed core tablet of essentially uniform cross-section having substantially exposed first and second opposed surfaces containing an active pharmaceutical ingredient and sheathed around the circumference thereof in an annular body of compressed powder or granular material formed by compression around the core tablet.
Patent NZ-541049-A (NZ)
Title: Use of 2-amino-2H-quinazoline derivatives for producing therapeutic agents
Inventor: SACHSE ROLF
IPC: A61K31/517
Filed: 2004-01-07
Abstract: Disclosed is the use of 2-amino-2H-quinazoline derivatives of the general chemical formula I wherein the substituents are disclosed within the specification, as well as their pharmaceutically compatible salts, for producing therapeutic agents for the treatment of myeloproliferative diseases and for bronchodilation in mammals.
Patent NZ-543002-A (NZ)
Title: Adaptor with gimbal mounted sensor
Inventor: MURRAY PETER GRAHAME
IPC: H05B37/02
Filed: 2004-04-02
Abstract: An adaptor (10) including a sensor (18), a gimbal housing (12) having a male connector (14) at one end and an female connector (16) at another end, wherein the male connector (14) is configured to connect with an electrical socket and the female connector (16) is configured to connect with an electrical device, and a circuit for selectively controlling the electrical device in response to the sensor (18). The gimbal housing (12) is adapted to rotate around the male connector (14) about a first axis and support the sensor (18) for independent rotation about a second axis perpendicular to the first axis so that the sensor (18) can be moved to a selectable sensing orientation.
Patent NZ-551850-A (NZ)
Title: Retractable syringe with trigger and lock
Inventor: BARROW-WILLIAMS TIM
IPC: A61M5/20
Filed: 2005-05-27
Abstract: An injection device 110 comprising a housing 112 adapted to receive a syringe 114 having a discharge nozzle, a drive that is acted upon and in turn acts upon the syringe 114, a trigger movable from a rest position, in which it causes the drive to be retained, to an active position, in which it no longer causes the drive to be so retained, thus allowing its contents to be discharged through the discharge nozzle, and an interlock member movable between a locking position, at which it prevents movement of the trigger from its rest position to its active position, and a releasing position, at which it allows movement of the trigger from its rest position to its active position, the device 110 having an indicator to show that it has been used, provided by the trigger being retained in its active position and activating upon said trigger moving to an active position, wherein the trigger and the interlock member include a latching projection and a corresponding latching surface against which the latching projection latches when the trigger is in its active position.
Patent NZ-552223-A (NZ)
Title: CD34+ hematopoietic cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
Inventor: GIANNI ALESSANDRO M
Filed: 2005-07-21
Abstract: Disclosed are CD34+ hematopoietic cells from the peripheral blood of growth-factor treated cancer patients transduced with the tumor necrosis factor-related apoptosis inducing ligand, with the proviso that said cells are not dendritic cells, and the use of said cells for the treatment of tumors.
Patent NZ-556160-A (NZ)
Title: Methods for treating adhesive capsulitis
Inventor: BADALAMENTE MARIE
IPC: A61K38/48
Filed: 2006-01-19
Abstract: Disclosed is the use of an effective amount of collagenase in the manufacture of a medicament for treating or preventing adhesive capsulitis in a subject in need of such treatment or prevention, wherein said treatment of prevention comprises delivering said medicament to collagenous adhesions in the shoulder.
Patent NZ-560244-A (NZ)
Title: Adjustable toggle and stop for a furniture mechanism
Inventor: LAPOINTE LARRY P
IPC: A47C1/034
Filed: 2006-04-13
Abstract: An article of furniture includes an actuation mechanism to enable a leg rest assembly to move between a stowed position and an extended position and be retained in intermediate positions. The mechanism includes a support shaft 28, a squared drive rod 26 spaced apart from the support shaft, and a toggle link 36, 46, coupled to the drive rod. Multiple apertures are coaxially aligned on the toggle link. The first end of a biasing element 52 is connected to one of the toggle link apertures 50 and the second end of the biasing element is a hook 54 that slidably engages the support shaft 28 along region 60. The spring force of the biasing element is operably variable by engaging the first end to different ones of the toggle link apertures. The biasing element slides to align itself on the support shaft where a biasing element length is minimized.
Patent NZ-565451-A (NZ)
Title: Substituted benzimidazoles and methods of preparation
Inventor: DIMITROFF MARTIN
IPC: C07D401/14
Filed: 2006-08-30
Abstract: Disclosed is a method for preparing a imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-amine of Formula (I) or a tautomer, stereoisomer, ester, or pharmaceutically acceptable salt thereof wherein, R1, R2, R3 and R4 is defined in the specification, a is 1, 2, 3, 4, or 5; b is 0, 1, 2, or 3; c is 1 or 2; the method comprising: (a) reacting a aniline of Formula (II) with a pyridine of Formula (III) under basic conditions to provide a pyridin-4-yloxyphenyl amine of Formula (IV), (wherein Q is NH2 or NO2; one of L1 or L2 is halo and the other of L1 or L2 is OH or an anion thereof; Z is cyano, COOR5, CH2OR5, CHO, or imidazol-2-yl substituted with one or two R4 groups and wherein R5 is hydrogen or a hydroxy protecting group; (b) when in the compound of Formula (IV) Z is cyano, COOR5 or CH2OR5, converting said compound to a compound of Formula 5 (IV) wherein Z is CHO; (c) when in the compound of Formula (IV) Z is cyano, converting the cyano functionality to an amidino functionality and reacting said amidino functionality with a compound of Formula (Va) under imidazole ring forming conditions; or when in the compound of Formula (IV) Z is CHO, reacting said compound with a compound of Formula (Vb) to provide a compound of Formula (VI) wherein Xa in Formula (Va) is a leaving group and R4p and R4q in Formula (Vb) are independently H or R4, provided that at least one of R4p and R4q is R4 and Xb is =O or =NHOH and provided that c is 1 when a compound of Formula (VI) is prepared from a compound of Formula (Va); (d) when in the compound of Formula (VI) Q is NO2, converting said compound to a compound of Formula (VI) wherein Q is NH2; (e) reacting the compound of Formula (VI) wherein Q is NH2 with a compound of Formula (VII) to provide a compound of Formula (VIII) or a tautomer thereof; (f) reacting the compound of Formula (VIII) or a tautomer thereof with a desulfurizing agent to provide a compound of Formula (I). Also disclosed is a imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-amine prepared by this method.
Patent NZ-567075-A (NZ)
Title: Fitness machine having a vibration absorbing support
Inventor: VAN DER MEER AUGUSTINUS LEONARDUS NICOLAAS
IPC: A61H23/00
Filed: 2005-09-06
Abstract: Disclosed is a fitness machine for training a body. The machine includes a frame with a vibration element, a vibration generator operatively coupled to the vibration element and at least one vibration absorbing frame support operatively coupled to the vibration generator. The vibration absorption level of the vibration absorbing frame support is adjustable. The fitness machine further includes at least one control system for controlling the vibration generator in response to a user input and for controlling the absorption level of the vibration absorbing frame support in response to a body mass of a user positioned on the vibration element such that the selectable training load levels are substantially equal for each user.
Patent NZ-577997-A (NZ)
Title: Demountable modular structure for high-efficiency dual level raised deck parking lots with herringbone parking stalls
Inventor: PAOLUCCI STEFANO
IPC: E04H6/10
Filed: 2007-10-30
Abstract: Disclosed is a modular structural framework to allow high efficiency car parking and car storage. The demountable modular structure for parking vehicles has on- ground and upper levels, comprising three parallel structure strips. The central strip is used as a drive aisle and the outer lateral strips have angled herringbone parking stalls. Each parallel structure strip is defined by two rows of vertical supporting elements offset from each other in the longitudinal direction of the structure strip so as to form between two adjacent couples of the vertical supporting elements, parallelogram-shaped ground surface portions. Each one of the vertical supporting elements being provided with a foundation base below it for resting on the ground and with a joint or node element above it for connection with the upper level of the structure strip. The structure also comprises a number of ties and/or struts for bracing the structure, connected with their ends to the node elements and to the bases. The upper level consists of an orthogonal network of main beams resting, through the node elements, on each one of the rows of vertical supporting elements. The secondary beams rest through the node elements, on the vertical supporting elements or fixed in orthogonal position to the main beams, and in rectangular or square floor slabs.
Patent NZ-585724-A (NZ)
Title: Microencapsulated enteric release system for delivering esterified essential oils with foods
Inventor: GAONKAR ANILKUMAR GANAPATI
IPC: A23L33/00
Filed: 2010-05-27
Abstract: A composition comprising: a functional ingredient; a non-active carrier; and an enteric matrix microencapsulating the functional ingredient and non-active carrier and comprising a food grade enteric polymer is disclosed, wherein the functional ingredient comprises at least about 10% esters wherein the esters are esterified essential oils that are configured to hydrolyse into parent, non-esterified essential oils. Preferably the functional ingredient comprises esters of thymol and linalool, i.e. thymyl ester to linalyl ester; the non-active carrier is a triglyceride selected from the group including soybean oil and canola oil; and the enteric matrix is selected from the group consisting of zein, shellac, calcium alginate and mixtures thereof. The disclosure also relates to a method comprising the steps of: (a) agitating a combination of water, an enteric matrix material, and an emulsifier at an appropriate pH to solubilise the enteric matrix material, the combination substantially free of organic solvents; (b) adding a functional ingredient to the combination, the active ingredient comprising at least 10% esters, wherein the esters are essential oils that are configured to hydrolyze into parent, non-esterified essential oils; (c) mixing the combination and functional ingredient to create an emulsion; and (d) agitating while titrating the emulsion with a crosslinking or precipitating agent in an amount effective to form a particulate precipitate, wherein the functional ingredient is homogenously dispersed throughout the precipitate.
Patent NZ-589309-A (NZ)
Title: New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
Inventor: COHEN DANIEL
IPC: A61P25/28
Filed: 2009-04-29
Abstract: Disclosed is the use of a composition comprising sulfisoxazole, or a salt, or sustained release formulation thereof, in the manufacture of a medicament for the treatment of Alzheimer's disease.
Patent NZ-590581-A (NZ)
Title: Slotted seismic clip for ceiling grid tee control joint allowing telescoping action
Inventor: TEDESCO LEE M
IPC: E04B7/04
Filed: 2009-06-26
Abstract: 590581 A seismic clip (10) is disclosed for bridging a gap (36) between grid tees (27, 28) of a suspended ceiling. The clip has a cruciform shape formed by four integral arms. The arms have an inverted U shape cross section to fit over the reinforcing bulb (26) of intersecting grid tees. At least one of the arms has a longitudinally extending fastener slot allowing a fastener (37) to be received through the slot and anchored to the bulb (26) of the tee. The slot is arranged to allow the respective grid tee (27) to telescope within the arm in the event of an unusual force being applied such as during an earthquake.
Patent NZ-591047-A (NZ)
Title: In vivo methods of monitoring biodistribution
Inventor: NICOLAI VLADIMIROVICH BOVIN
IPC: A61K49/00
Filed: 2011-02-09
Abstract: ABSTRACT - 591047 The disclosure relates to method of radiolabelling a biological entity comprising the step of contacting a suspension of the biological entity with an iodinated (125I) construct of the structure F-S-L for a time and at a temperature sufficient to allow localisation of the 125I to the surface of the biological entity where F comprises an iodinated histidine (His) residue or an iodinated tyrosine (Tyr) residue, S is a spacer covalently linking F to L, and L is a lipid, wherein the biological entity is a cell or an enveloped virus.
Patent NZ-597853-A (NZ)
Title: Modified agrin-fragment capable of restoring muscle strength for use as a medicament
Inventor: HETTWER STEFAN
IPC: A61K38/17
Filed: 2010-09-01
Abstract: 597853 Disclosed is a modified agrin fragment having in vivo activity for use as medicament, the fragment comprising at least the domains LG2 and LG3 of human or mouse agrin in a covalently interlinked form, and modified in such a way that the fragment cannot be cleaved by neurotrypsin, wherein the modified agrin fragment is not C44y0z0K/A.
Patent NZ-600731-A (NZ)
Title: Oxyntomodulin peptide analogue
Inventor: ALSINA-FERNANDEZ JORGE
IPC: A61K38/17
Filed: 2010-12-15
Abstract: Disclosed is a oxyntomodulin peptide analogue comprising the amino acid sequence: His-(Aib)-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Lys-Lys-Ala-Gln-Glu-Phe-Val-Gln-Trp-Leu-Leu-Asn-(Aib)-Gly-Arg-Asn-Arg-Asn-Asn-Ile-Ala-Xaa38-Xaa39 (SEQ ID NO: 5) wherein Xaa38 is Cys, Cys-PEG, or is absent; Xaa39 is Cys, Cys-PEG, or is absent; and wherein the C-terminal amino acid is optionally amidated.
Patent NZ-603120-A (NZ)
Title: Product gas concentrator and method associated therewith
Inventor: SPRINKLE THOMAS B
IPC: B01D46/46
Filed: 2008-04-21
Abstract: 603120 Disclosed is an apparatus for providing a concentrated product gas. The apparatus has first and second sieve tanks (300) arranged to separate one or more adsorbable components from a pressurized source gaseous mixture in alternating and opposing pressurization and purging cycles to form the concentrated product gas. A controller is in operative communication with the first and second sieve tanks to selectively control the pressurization and purging cycles over a plurality of predetermined altitude ranges while maintaining an acceptable purity level for the concentrated product gas.
Patent NZ-603734-A (NZ)
Title: Mobile communication method and mobile station
Inventor: IWAMURA MIKIO
IPC: H04W24/10
Filed: 2011-04-28
Abstract: 603734 Disclosed is a mobile station configured to be able to communicate with a radio base station by using a primary carrier and one or a plurality of secondary carriers having different carrier frequencies. A serving cell is present in each of the primary carrier and the secondary carriers. The method includes a step of transmitting, by the radio base station, measurement control information including a carrier to be measured and a reporting condition, to the mobile station. The method also includes a step B of transmitting, by the mobile station, a measurement report including a measurement result of the carrier to be measured, to the radio base station, when the reporting condition is satisfied. In the step B, when a measurement value of a radio quality in a non-serving cell of the secondary carrier within the carrier to be measured is larger than a sum of a measurement value of a radio quality in a serving cell of the secondary carrier within the carrier to be measured and a predetermined offset value for a predetermined period, the mobile station determines that the reporting condition is satisfied.
Patent NZ-615890-A (NZ)
Title: Marine conversion of a diesel engine
Inventor: BUNN MURRAY NOEL
IPC: F02B61/04
Filed: 2012-09-27
Abstract: 615890 Disclosed is an internal combustion engine (100) having a front and rear and adapted or converted for marine use. Engines converted from marine use can suffer from overheating due to being housed in a closed compartment; therefore it is important to ensure that the engine does not heat beyond the limits set out by marine regulations. The internal combustion engine (100) comprises a turbocharger (107). The turbocharger (107) is driven by exhaust gas pressure. The engine (100) is internally cooled by a first closed coolant circuit. Flow of coolant is caused by a coolant pump (106) which is connected through one or more non-mingling heat exchangers (105, 108) to a flow of raw water actuated by a pump (110) in a second open circuit. The engine (100) includes at least one bank of combustion chambers (102) and each chamber (102) has a corresponding exhaust port. Each bank of combustion chambers (102) comprises one exhaust manifold (101). The exhaust manifold (101) is formed from a solid thermally conductive mass which includes a thick wall surrounded by a duct and is capable of carrying hot exhaust gases from the exhaust ports. The wall is sufficiently thick to include a plurality of internal conduits or galleries. The exhaust manifold (101) further comprises a closed end and an open end. Coolant apertures (101E, 101F, 101G, 101H) are formed through a manifold face of the engine (100). Each aperture (101E, 101F, 101G, 101H) creates an opening into one of the plurality of conduits or galleries which surrounds a corresponding combustion chamber. A series of coolant channels (101A, 101B, 101C, 101D) each connect to a corresponding coolant aperture (101E, 101F, 101G, 101H). The coolant channels (101A, 101B, 101C, 101D include the exhaust manifold (101) within the closed coolant circuits and limit a temperature of the exhaust manifold (101) by removing heat into the coolant. The exhaust manifold (101) further comprises outlets which are aligned with corresponding inlets of an exhaust manifold extension (104) which serve to separately carry the coolant (104B) and the gas outflow (104A) from the exhaust manifold (101) to the turbocharger (107). Each coolant channel (101A, 101B, 101C, 101D is provided with a predetermined resistance to flow of coolant.
Patent NZ-622048-A (NZ)
Title: Hybrid polypeptides including meningococcal fhbp sequences
Inventor: RAPPUOLI RINO
IPC: C07K14/22
Filed: 2010-08-27
Abstract: Disclosed is a polypeptide comprising a first immunogenic amino acid sequence and a second immunogenic amino acid sequence, wherein the first immunogenic amino acid sequence comprises an amino acid sequence set forth in SEQ ID NO: 20, subject to the proviso that the polypeptide does not comprise an amino acid sequence set forth in SEQ ID NO: 23, wherein the sequences are as defined in the complete specification. Also disclosed is the use of said polypeptide in the preparation of a medicament for the treatment or prevention of infection by Neisseria meningitides.